Join

Compare · MRK vs MURF

MRK vs MURF

Side-by-side comparison of Merck & Company Inc. (MRK) and Murphy Canyon Acquisition Corp. (MURF): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both MRK and MURF operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • MRK carries a market cap of $204.35B.
  • MRK has hit the wire 9 times in the past 4 weeks while MURF has been quiet.
  • MRK has more recent analyst coverage (25 ratings vs 0 for MURF).
MetricMRKMURF
Company
Merck & Company Inc.
Murphy Canyon Acquisition Corp.
Price
-
-
Market cap
$204.35B
-
1M return
-
-
1Y return
-
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
2022
News (4w)
9
0
Recent ratings
25
0
MRK

Merck & Company Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

MURF

Murphy Canyon Acquisition Corp.

Murphy Canyon Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on identifying businesses in the real estate industry, including construction, homebuilding, real estate owners and operators, arrangers of financing, insurance, and other services for real estate, and adjacent businesses and technologies targeting the real estate space. The company was incorporated in 2021 and is based in San Diego, California.

Latest MRK

Latest MURF